Amy E Armstrong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6120474/publications.pdf

Version: 2024-02-01

20	761	840776 11	839539 18
papers	citations	h-index	g-index

20	20	20	1514
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro-Oncology, 2022, 24, 1776-1789.	1.2	37
2	Plexiform neurofibroma: shedding light on the investigational agents in clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 31-40.	4.1	1
3	LINC-08. Neuro-Oncology tumor board â€“ one-year experience of international collaboration. Neuro-Oncology, 2022, 24, i163-i164.	1.2	0
4	OTHR-18. A pilot study evaluating the access, utilization, and patient satisfaction of basic skin care products among pediatric patients prescribed medications that target the mitogen-activated protein kinase pathway. Neuro-Oncology, 2022, 24, i150-i151.	1.2	0
5	A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses. Pediatric Neurology, 2022, 134, 1-6.	2.1	2
6	Cabozantinib for neurofibromatosis type 1â€“related plexiform neurofibromas: a phase 2 trial. Nature Medicine, 2021, 27, 165-173.	30.7	46
7	Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1. Pediatric Blood and Cancer, 2020, 67, e28372.	1.5	3
8	Neurofibromatosis type 1-related tumours in paediatrics: an evolving treatment landscape. The Lancet Child and Adolescent Health, 2020, 4, 488-490.	5.6	5
9	Noninvasive Diagnosis of Infection Using Plasma Next-Generation Sequencing: A Single-Center Experience. Open Forum Infectious Diseases, 2019, 6, .	0.9	84
10	Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Human Molecular Genetics, 2019, 28, 2752-2762.	2.9	54
11	Cellâ€free DNA nextâ€generation sequencing successfully detects infectious pathogens in pediatric oncology and hematopoietic stem cell transplant patients at risk for invasive fungal disease. Pediatric Blood and Cancer, 2019, 66, e27734.	1.5	73
12	Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation. Pediatric Blood and Cancer, 2019, 66, e27493.	1.5	7
13	Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants. Journal of Pediatric Hematology/Oncology, 2018, 40, 31-35.	0.6	26
14	A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Childrenâ€™s Oncology Group study. PLoS ONE, 2018, 13, e0208936.	2.5	35
15	The Impact of High-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1 on Transplant-related Outcomes in Single-unit Umbilical Cord Blood Transplantation in Pediatric Patients. Journal of Pediatric Hematology/Oncology, 2017, 39, 26-32.	0.6	11
16	A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nature Genetics, 2017, 49, 1487-1494.	21.4	255
17	Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome. Pediatric Blood and Cancer, 2015, 62, 2007-2010.	1.5	12
18	Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. Pediatric Blood and Cancer, 2014, 61, 949-950.	1.5	9

#	Article	IF	Citations
19	Graft-versus-host disease after solid organ transplantation: A single center experience and review of literature. Annals of Transplantation, 2012, 17, 133-139.	0.9	48
20	Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine, 2011, 29, 2705-2711.	3.8	53